Ozempic lessens odds of complications from kidney disease: Study
- Semaglutide is compound found in diabetes drug Ozempic
- People who used it reduced their risk of death from kidney disease
- Ozempic manufacturer Novo Nordisk published headline results in March
ovp test
Male shot by female at Shreveport apartment
Class to create biodiverse backyard
Rules for outbursts at Caddo School Board Meeting
(NewsNation) — Semaglutide, a compound found in drugs such as Ozempic, reduced the risk of complications for those with chronic kidney disease and Type 2 diabetes, according to a study published Friday in the New England Journal of Medicine.
Novo Nordisk, the manufacturer of the diabetes drug Ozempic, which can be prescribed off-label for weight loss, published the headline results of the multiyear study in March. About 3,533 people with chronic kidney disease or Type 2 diabetes participated, with half given semaglutide and the others getting a placebo.
Those who had taken the semaglutide, researchers said, were able to cut their odds of death from kidney disease complications by 24%. People who took semaglutide also lowered their likelihood of experiencing a major cardiovascular event by 18% and other causes of death by 20%.
Novo ended its trial nearly a year ahead of schedule last October in response to positive results.
NewsNation digital producer Taylor Delandro contributed to this report.
